Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Glioblastoma Multiforme (GBM) Treatment Market Size Changed, over the years?

In the past few years, the Glioblastoma Multiforme (GBM) treatment market has experienced swift growth. The market, which is set to expand from $2.48 billion in 2024 to $2.74 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 10.2%. The phenomenal growth during the historic period can be linked to a surge in incidence and prevalence, advancements in diagnostic methodology, increased resources for clinical trials and research, collaborations and strategic partnerships, and a better comprehension of tumor biology.

How Much Will the Glioblastoma Multiforme (GBM) Treatment Market Be Worth in 2029?

Over the upcoming years, the glioblastoma multiforme (GBM) treatment market size is predicted to experience a swift expansion. The expectation is that it will escalate to a staggering $4.1 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.6%. The projected growth in this period is credited to the introduction of immunotherapies and the advancements in precision medicine, along with an increased understanding of genetic markers, amplified patient advocacy and awareness, and governmental assistance for rare illnesses. Key trends during this forecast period are anticipated to be the investigation into combination therapies, the incorporation of artificial intelligence in diagnosis and treatment plans, an uptick in the embrace of immunotherapeutic tactics, and the development of advanced medical tools and apparatus.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

Which is the Largest Company in the Glioblastoma Multiforme (GBM) Treatment Market?

Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

What Are the Main Market Drivers in the Glioblastoma Multiforme (GBM) Treatment Industry?

The rise in brain health disorders is projected to boost the evolution of the glioblastoma multiforme (GBM) treatment market. Brain health disorders consist of any negative deviation from normal functioning of the brain, nerves throughout the body and the spinal cord. Factors contributing to the growing occurrence of such conditions, particularly glioblastoma multiforme (GBM), include an aging demographic, weakening immune systems, over-diagnosis, exposure to ionising radiation, air pollutants and other variables. These necessitate treatments to enhance overall health and well-being. For instance, a 2022 report by the American Cancer Society, a non-profit organisation committed to cancer eradication, highlighted roughly 25,050 malignant brain or spinal cord cancer instances registered within the US. Thus,rising occurrence of brain health disorders is fueling the expansion of the glioblastoma multiforme (GBM) treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8803&type=smp

How Is the Glioblastoma Multiforme (GBM) Treatment Market Segments Structured?

The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy

2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Surgery: Tumor Resection, Biopsy Procedures

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy

3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens

4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents

5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment

6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

What Strategic Trends Are Transforming the Glioblastoma Multiforme (GBM) Treatment Market?

Key players in the market are concentrated on innovating wearable and portable devices to maintain their market position. These advancements aim to provide users with improved functionality, ease, and comfort, meeting the rising demand for accessible and efficacious healthcare solutions. For example, Novocure, an oncology company based in Jersey, introduced Optune Gio, a wearable, portable treatment system for newly diagnosed glioblastoma (GBM) patients, in 2023. The device, approved by the FDA, utilizes Tumor Treating Fields (TTFields), alternating electric fields that interfere with the division of cancer cells, potentially increasing survival rates. Weighing just 2.7 pounds, Optune Gio has been designed for comfort, enabling patients to use it during their daily routine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Glioblastoma Multiforme (GBM) Treatment Market?

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803

This Report Delivers Insight On:

1. How big is the glioblastoma multiforme (gbm) treatment market, and how is it changing globally?

2. Who are the major companies in the glioblastoma multiforme (gbm) treatment market, and how are they performing?

3. What are the key opportunities and risks in the glioblastoma multiforme (gbm) treatment market right now?

4. Which products or customer segments are growing the most in the glioblastoma multiforme (gbm) treatment market?

5. What factors are helping or slowing down the growth of the glioblastoma multiforme (gbm) treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model